AGY — Allergy Therapeutics Share News
0.000.00%
Last trade - 00:00- £300.80m
- £317.46m
- £55.04m
Brief: Allergy Therapeutics Extends Cash Runway Into Q1 Of FY25
Allergy Therapeutics - Update on funding
Allergy Therapeutics - Interim Results for six months ended 31 Dec 2023
Allergy Therapeutics - VLP Peanut PROTECT Trial Update
RCS - Allergy Therapeutics - VLP Peanut PROTECT Trial Update
Brief: Allergy Therapeutics Appoints Shaun Furlong As Executive Director
Allergy Therapeutics - Appointment of Shaun Furlong to Board of Directors
Brief: Allergy Therapeutics Expects Revenue For 6 Months Ended 31 Dec 2023 To Be £33.6 Mln
Allergy Therapeutics - Half-Year Trading Update 2024
Allergy Therapeutics - Notice of 2023 Annual General Meeting
Allergy Therapeutics - Publication of Annual Report and Accounts 2023
Brief: Allergy Therapeutics Says Amended Facility Provides £40 Mln Secured Loan Facility
Allergy Therapeutics - Amendment to existing Facility Agreement
Brief: Allergy Therapeutics Says Ordinary Shares To Be Suspended From Trading On AIM
Allergy Therapeutics - Annual Report and Accounts Delayed
Allergy Therapeutics - PDMR dealing and Total Voting Rights
Brief: Allergy Therapeutics Says G306 Phase III Trial Meets Key Endpoints
Brief: Allergy Therapeutics Says Group Extended Cash Runway Towards End Of Jan 2024
Allergy Therapeutics - Update on funding